Comparison of the therapeutic effects of CTVP and CTOP regimens as initial treatment for non-Hodgkin's lymphoma

Yun Hou, Huaqing Wang, Kai Fu, Xianming Liu, Huilai Zhang, Zhengzi Qian, Lanfang Li, Shiyong Zhou, Xiuzhen Cui, Xishan Hao

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Objective: To compare the efficacy and toxicity of CTVP (with VDS) and CTOP (with VCR) regimens as an initial treatment for Non-Hodgkin Lymphoma. Methods: From January 2000 to December 2005, 288 patients with Non-Hodgkin Lymphoma were treated in Tianjin Cancer Hospital with combined chemotherapy, including CTVP and CTOP, among which 162 were treated by CTVP and 118 by CTOP regimen. The rate of response, toxicity and long-term survival for the 2 regimens were analyzed retrospectively. Results: The clinical characteristics of the 2 groups were quite similar (P>0.05). A total of 272 patients were eligible. The response rates for CTVP and CTOP were 73.13% and 72.32%, the clinical benefit rates were 91.88% and 90.18%, respectively (P>0.05). Major toxicity was myelosuppression, Gl toxicity, fatigue, neurotoxicity and alopecia. Incidence of neurotoxicity was lower in the CTVP group than in the CTOP group (14.81% vs. 31.36%, P< 0.05). Median follow-up was 32 months (ranging from 2 to 71 months). The 5-year overall survival rates for the CTVP and CTOP groups were 43.2% and 22.3%, respectively (P<0.05). Conclusion: VDS in the CTVP regimen may be more effective as an initial treatment for Non-Hodgkin lymphoma, with lower toxicity and better long-term survival. A randomized clinical trial is required to confirm these results.

Original languageEnglish (US)
Pages (from-to)1065-1068
Number of pages4
JournalChinese Journal of Clinical Oncology
Volume37
Issue number18
DOIs
StatePublished - Dec 1 2010

Fingerprint

Therapeutic Uses
Non-Hodgkin's Lymphoma
Therapeutics
Cancer Care Facilities
Survival
Alopecia
Fatigue
phenylalanyl-cyclo(cysteinyltyrosyl-tryptophyl-ornithyl-threonyl-penicillamine)threoninamide
Survival Rate
Randomized Controlled Trials
Drug Therapy
Incidence

Keywords

  • Doxorubicin
  • Non-Hodgkin Lymphoma
  • Vincristine
  • Vindesine

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Comparison of the therapeutic effects of CTVP and CTOP regimens as initial treatment for non-Hodgkin's lymphoma. / Hou, Yun; Wang, Huaqing; Fu, Kai; Liu, Xianming; Zhang, Huilai; Qian, Zhengzi; Li, Lanfang; Zhou, Shiyong; Cui, Xiuzhen; Hao, Xishan.

In: Chinese Journal of Clinical Oncology, Vol. 37, No. 18, 01.12.2010, p. 1065-1068.

Research output: Contribution to journalArticle

Hou, Yun ; Wang, Huaqing ; Fu, Kai ; Liu, Xianming ; Zhang, Huilai ; Qian, Zhengzi ; Li, Lanfang ; Zhou, Shiyong ; Cui, Xiuzhen ; Hao, Xishan. / Comparison of the therapeutic effects of CTVP and CTOP regimens as initial treatment for non-Hodgkin's lymphoma. In: Chinese Journal of Clinical Oncology. 2010 ; Vol. 37, No. 18. pp. 1065-1068.
@article{4b17a226d77f46869c9c68e68cc520e1,
title = "Comparison of the therapeutic effects of CTVP and CTOP regimens as initial treatment for non-Hodgkin's lymphoma",
abstract = "Objective: To compare the efficacy and toxicity of CTVP (with VDS) and CTOP (with VCR) regimens as an initial treatment for Non-Hodgkin Lymphoma. Methods: From January 2000 to December 2005, 288 patients with Non-Hodgkin Lymphoma were treated in Tianjin Cancer Hospital with combined chemotherapy, including CTVP and CTOP, among which 162 were treated by CTVP and 118 by CTOP regimen. The rate of response, toxicity and long-term survival for the 2 regimens were analyzed retrospectively. Results: The clinical characteristics of the 2 groups were quite similar (P>0.05). A total of 272 patients were eligible. The response rates for CTVP and CTOP were 73.13{\%} and 72.32{\%}, the clinical benefit rates were 91.88{\%} and 90.18{\%}, respectively (P>0.05). Major toxicity was myelosuppression, Gl toxicity, fatigue, neurotoxicity and alopecia. Incidence of neurotoxicity was lower in the CTVP group than in the CTOP group (14.81{\%} vs. 31.36{\%}, P< 0.05). Median follow-up was 32 months (ranging from 2 to 71 months). The 5-year overall survival rates for the CTVP and CTOP groups were 43.2{\%} and 22.3{\%}, respectively (P<0.05). Conclusion: VDS in the CTVP regimen may be more effective as an initial treatment for Non-Hodgkin lymphoma, with lower toxicity and better long-term survival. A randomized clinical trial is required to confirm these results.",
keywords = "Doxorubicin, Non-Hodgkin Lymphoma, Vincristine, Vindesine",
author = "Yun Hou and Huaqing Wang and Kai Fu and Xianming Liu and Huilai Zhang and Zhengzi Qian and Lanfang Li and Shiyong Zhou and Xiuzhen Cui and Xishan Hao",
year = "2010",
month = "12",
day = "1",
doi = "10.3969/j.issn.1000-8179.2010.18.010",
language = "English (US)",
volume = "37",
pages = "1065--1068",
journal = "Chinese Journal of Clinical Oncology",
issn = "1672-7118",
publisher = "China Anti-Cancer Association",
number = "18",

}

TY - JOUR

T1 - Comparison of the therapeutic effects of CTVP and CTOP regimens as initial treatment for non-Hodgkin's lymphoma

AU - Hou, Yun

AU - Wang, Huaqing

AU - Fu, Kai

AU - Liu, Xianming

AU - Zhang, Huilai

AU - Qian, Zhengzi

AU - Li, Lanfang

AU - Zhou, Shiyong

AU - Cui, Xiuzhen

AU - Hao, Xishan

PY - 2010/12/1

Y1 - 2010/12/1

N2 - Objective: To compare the efficacy and toxicity of CTVP (with VDS) and CTOP (with VCR) regimens as an initial treatment for Non-Hodgkin Lymphoma. Methods: From January 2000 to December 2005, 288 patients with Non-Hodgkin Lymphoma were treated in Tianjin Cancer Hospital with combined chemotherapy, including CTVP and CTOP, among which 162 were treated by CTVP and 118 by CTOP regimen. The rate of response, toxicity and long-term survival for the 2 regimens were analyzed retrospectively. Results: The clinical characteristics of the 2 groups were quite similar (P>0.05). A total of 272 patients were eligible. The response rates for CTVP and CTOP were 73.13% and 72.32%, the clinical benefit rates were 91.88% and 90.18%, respectively (P>0.05). Major toxicity was myelosuppression, Gl toxicity, fatigue, neurotoxicity and alopecia. Incidence of neurotoxicity was lower in the CTVP group than in the CTOP group (14.81% vs. 31.36%, P< 0.05). Median follow-up was 32 months (ranging from 2 to 71 months). The 5-year overall survival rates for the CTVP and CTOP groups were 43.2% and 22.3%, respectively (P<0.05). Conclusion: VDS in the CTVP regimen may be more effective as an initial treatment for Non-Hodgkin lymphoma, with lower toxicity and better long-term survival. A randomized clinical trial is required to confirm these results.

AB - Objective: To compare the efficacy and toxicity of CTVP (with VDS) and CTOP (with VCR) regimens as an initial treatment for Non-Hodgkin Lymphoma. Methods: From January 2000 to December 2005, 288 patients with Non-Hodgkin Lymphoma were treated in Tianjin Cancer Hospital with combined chemotherapy, including CTVP and CTOP, among which 162 were treated by CTVP and 118 by CTOP regimen. The rate of response, toxicity and long-term survival for the 2 regimens were analyzed retrospectively. Results: The clinical characteristics of the 2 groups were quite similar (P>0.05). A total of 272 patients were eligible. The response rates for CTVP and CTOP were 73.13% and 72.32%, the clinical benefit rates were 91.88% and 90.18%, respectively (P>0.05). Major toxicity was myelosuppression, Gl toxicity, fatigue, neurotoxicity and alopecia. Incidence of neurotoxicity was lower in the CTVP group than in the CTOP group (14.81% vs. 31.36%, P< 0.05). Median follow-up was 32 months (ranging from 2 to 71 months). The 5-year overall survival rates for the CTVP and CTOP groups were 43.2% and 22.3%, respectively (P<0.05). Conclusion: VDS in the CTVP regimen may be more effective as an initial treatment for Non-Hodgkin lymphoma, with lower toxicity and better long-term survival. A randomized clinical trial is required to confirm these results.

KW - Doxorubicin

KW - Non-Hodgkin Lymphoma

KW - Vincristine

KW - Vindesine

UR - http://www.scopus.com/inward/record.url?scp=84873432683&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84873432683&partnerID=8YFLogxK

U2 - 10.3969/j.issn.1000-8179.2010.18.010

DO - 10.3969/j.issn.1000-8179.2010.18.010

M3 - Article

VL - 37

SP - 1065

EP - 1068

JO - Chinese Journal of Clinical Oncology

JF - Chinese Journal of Clinical Oncology

SN - 1672-7118

IS - 18

ER -